RotaTeq FDA Approval History
FDA Approved: Yes (First approved February 3, 2006)
Brand name: RotaTeq
Generic name: rotavirus vaccine, live, oral, pentavalent
Company: Merck & Co., Inc.
Treatment for: Rotavirus Gastroenteritis
RotaTeq (rotavirus vaccine, live, oral, pentavalent) is an oral, three-dose vaccine given to infants between the ages of six to 32 weeks for the prevention of rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children.
Development Timeline for RotaTeq
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.